Who Supplies Bortezomib to India from GERMANY

To import finished pharmaceutical formulations containing Bortezomib into India, the foreign manufacturer must obtain an Import Registration Certificate and an Import License from the Central Drugs Standard Control Organization (CDSCO). The application requires submission of Form 40 or 41, along with a No Objection Certificate (NOC) from the Drug Controller General of India (DCGI). The registration process includes providing detailed product information, manufacturing site details, and compliance with Good Manufacturing Practices (GMP). The timeline for import drug registration varies but typically ranges from 6 to 12 months, depending on the completeness of the application and regulatory reviews. For Bortezomib formulations under HS Code 30049049, specific requirements include stability data (preferably ICH Zone IV), a Certificate of Pharmaceutical Product (CoPP), and a Certificate of Analysis (CoA) for each batch. Additionally, the product must comply with the Indian Pharmacopoeia standards.

Imported Bortezomib formulations must undergo quality testing at CDSCO-approved laboratories in India. Each batch requires a CoA, confirming compliance with Indian Pharmacopoeia standards. Stability data, preferably from ICH Zone IV studies, must be provided to demonstrate product stability under Indian climatic conditions. Port inspection by customs drug inspectors is mandatory to verify the authenticity and quality of the imported products. If a batch fails quality testing, it may be rejected, leading to re-exportation or destruction, depending on the regulatory decision.

In April 2025, the Indian government introduced new regulations requiring import registration and licenses for all imported medicines, including finished formulations containing Bortezomib. This policy aims to prevent the sale of unapproved or illegal medicines in the Indian market. The implementation of the Production Linked Incentive (PLI) scheme has also impacted the import of finished formulations, encouraging domestic manufacturing and reducing dependency on imports. Bilateral agreements between India and Germany have facilitated smoother trade relations, but no specific Free Trade Agreement (FTA) exists between the two countries as of April 2026.

India imports finished Bortezomib formulations primarily due to the demand for patented and branded products not manufactured domestically. Specific dosage forms, such as subcutaneous injections, are often sourced from international markets. Domestic capacity for Bortezomib formulations is limited, leading to a reliance on imports to meet patient needs. The market size for Bortezomib formulations in India is substantial, with total imports valued at $21.9 million across 200 exporters to 109 countries.

The Basic Customs Duty (BCD) for Bortezomib formulations under HS Code 30049049 is 10%. A Social Welfare Surcharge (SWS) of 10% on the BCD is applicable. Integrated Goods and Services Tax (IGST) is levied on imports, with the rate depending on the product classification. Anti-dumping duties are not currently imposed on Bortezomib formulations. Exemption notifications are not applicable for Germany-origin products under the current trade agreements. The total landed duty percentage varies based on the product's value and applicable taxes.

India sources Bortezomib formulations from Germany due to the high quality and compliance with international GMP standards. German manufacturers often hold patents for specific formulations, providing a competitive advantage. While other suppliers, such as China and the United States, also export Bortezomib formulations to India, Germany's reputation for quality and innovation makes it a preferred source. Germany's share in the Indian Bortezomib import market is significant, with a total import value of $12.2K USD from Germany across 2 shipments.

India imports Bortezomib formulations from Germany due to the high quality and compliance with international GMP standards. German manufacturers often hold patents for specific formulations, providing a competitive advantage. The specialized nature of certain dosage forms, such as subcutaneous injections, necessitates sourcing from international markets. Germany's advanced pharmaceutical manufacturing capabilities and adherence to stringent quality controls make it a preferred source for these formulations.

Compared to other origins like China and the United States, Germany offers superior quality assurance, adherence to international GMP standards, and innovative formulations. While China may offer cost advantages, concerns about quality and regulatory compliance are prevalent. The United States provides high-quality products but at a higher cost. Germany's unique advantage lies in its balance of quality, innovation, and cost-effectiveness, making it a preferred source for Bortezomib formulations.

Indian importers face risks such as single-source dependency, currency fluctuations, regulatory changes, and potential shipping disruptions. Past shortages have occurred due to manufacturing issues in exporting countries. To mitigate these risks, importers should diversify suppliers, monitor currency trends, stay updated on regulatory changes, and maintain buffer stocks.

1. 1Dual-Sourcing: Engage multiple suppliers to reduce dependency on a single source.
2. 2Inventory Planning: Maintain adequate stock levels to buffer against supply chain disruptions.
3. 3Payment Terms: Negotiate favorable terms such as Letters of Credit (LC) or Documents Against Payment (DA/DP).
4. 4Minimum Order Quantities (MOQs): Align order quantities with demand forecasts to optimize inventory costs.
5. 5Supplier Qualification: Conduct thorough due diligence to ensure supplier reliability and compliance with quality standards.

1. DGFT Importer Exporter Code (IEC): Obtain an IEC from the